Medtronic Reports Third Quarter Fiscal 2021 Financial Results
News provided by
Share this article
- Q3 GAAP Diluted EPS of $0.94; Q3 Non-GAAP Diluted EPS of $1.29
DUBLIN, Feb. 23, 2021 /PRNewswire/ Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2021, which ended January 29, 2021.
The company reported third quarter worldwide revenue of $7.775 billion, an increase of 0.8 percent as reported and a decrease of 1.0 percent on an organic basis, which adjusts for the $136 million benefit of foreign currency translation. Unless otherwise stated, all revenue growth rates in this press release are stated on an organic basis, which adjusts for the impact of foreign currency translation. There were no acquisitions made in the last year that had a significant impact on the company s or any individual segment s third quarter revenue growth.
Vice President, Head of Investor Relations
Good morning and welcome to Medtronic s Fiscal Year 2021 Third Quarter Earnings Video Webcast. I m Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations.
Before we start the prepared remarks, I m going to share with you a few details to keep in mind about today s webcast. Joining me today are Geoff Martha, Medtronic Chairman and Chief Executive Officer; and Karen Parkhill, Medtronic Chief Financial Officer. Geoff and Karen will provide comments on the results of our third quarter, which ended on January 29, 2021. After our prepared remarks, we ll take questions from the sell-side analysts that cover the Company, and today s event should last about an hour.
Published: Dec 18, 2020 By Alex Keown
Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Kurtz held a number of leadership positions at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk.
Medtronic plc - Consensus Indicates Potential 10 9% Upside - DirectorsTalk Interviews directorstalkinterviews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from directorstalkinterviews.com Daily Mail and Mail on Sunday newspapers.